Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Am J Kidney Dis. 2013 Jun 12;62(5):10.1053/j.ajkd.2013.04.013. doi: 10.1053/j.ajkd.2013.04.013

Figure 1.

Figure 1

A propose schema of the development of mineral bone disorder in patients with CKD. A diseased kidney is unable to excrete (UPV) absorbed dietary phosphate, resulting in increased serum inorganic phosphate (Pi). This triggers an increase in parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23), both of which inhibit renal tubular phosphate absorption, and increase phosphate excretion. In addition, FGF-23 inhibits intestinal phosphate absorption, helping to mitigate the increase in the phosphate burden. Abbreviation: GI, gastrointestinal.